Aprea Therapeutics, Inc. (APRE) Stock Score, Valuation & Financial Research

Aprea Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for APRE

Aprea Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.64. These figures are a research snapshot, not a buy or sell recommendation.

What Aprea Therapeutics, Inc. does

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Aprea Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate product revenue. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its pipeline of small molecule cancer therapeutics.

Products and services

  • The company is developing a pipeline of precision oncology therapeutics, primarily focusing on synthetic lethality, including its lead clinical-stage candidate APR-1051, a WEE1 kinase inhibitor, and ATRN-119 (Mosipasertib), an ATR kinase inhibitor.

Brands and product families

  • APR-1051 — Lead clinical-stage WEE1 kinase inhibitor candidate. Source
  • ATRN-119 (Mosipasertib) — ATR kinase inhibitor candidate. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various unnamed third-party CROs to conduct its clinical trials and manage data collection. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes unnamed third-party CMOs for the manufacturing of its drug candidates for clinical use. Source

Competitors and product-market comparisons

  • AstraZeneca — Competes in the development of WEE1 and ATR kinase inhibitors for oncology indications. Source
  • Merck & Co. — Competes in the development of DNA damage response (DDR) inhibitors. Source

Business strengths to evaluate

  • Focused pipeline of internally discovered synthetic lethality-based cancer therapeutics Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Significant need for additional capital to fund clinical development Source
  • Dependence on third-party clinical trial and manufacturing partners Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

APRE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.64
Market capitalization:
7.87M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -12.31M
Free cash flow:
USD -12.89M
Cash:
USD 41.23M
Total debt:
USD 0.00
EPS:
USD -1.08

What stands out

  • Free cash flow is USD -12.89M, negative for the stored period.
  • The balance sheet shows USD 41.23M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 41.23M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for APRE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can APRE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is APRE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for APRE to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of APRE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research APRE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.